Please login to the form below

Not currently logged in
Email:
Password:

IFPMA names new communications director

Helen Gallagher joins the association from Ferring Pharmaceuticals

IFPMA has appointed Helen Gallagher as  its new communications director, a role that will see her act as a key spokesperson for the global biopharmaceutical industry trade body in its interaction with stakeholders and the wider global health community.

She said: “I look forward to getting the message out there of the many contributions that the R&D-based biopharmaceutical industry had made, and will make, to improve public health and to enable government to meet ambitious goals such as universal health coverage, global health security and continued innovation in areas of high unmet health needs such as antimicrobial resistance.

“I look forward to working with the IFPMA team to help strengthen the industry voice, build bridges among diverse global health actors, champion solutions and demonstrate that we are an essential partner in resolving health problems globally.”

Prior to her new role at IFPMA, Gallagher headed the corporate communications position at Ferring Pharmaceuticals for 12 years and she was also responsible for its corporate social responsibility programme and led its CSR taskforce.

Her 20-year career in health and biopharmaceutical communications has seen her serve in numerous capacities for Manning Selvage & Lee, Cohn & Wolfe, The Rowland Company and Ciba Speciality Chemicals.

Thomas Cueni, director general, IFPMA, said: “Helen will be instrumental in articulating our value proposition, building partnership and alliances, and representing our industry in discussions with permanent missions to the United Nations, intergovernmental organisations and other non-governmental organisations, foundations and academic institutions.”

13th November 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics